Trial Profile
Correlative Studies in Conjunction with A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 01 Sep 2011 New trial record